GILEAD SCIENCES, INC. is 16.4x more valuable than Krystal Biotech, Inc. by market capitalization ($150.83 B vs $9.21 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | KRYS | GILD |
|---|---|---|
| Market cap | $9.21 B | $150.83 B |
| US-listed rank | #989 | #99 |
| Revenue (latest FY) | $389.13M | $29.44B |
| Net income (latest FY) | $204.83M | $8.51B |
| Net margin | 52.6% | 28.9% |
| P/E (trailing FY) | 45.0 | 17.7 |
| SEC filings | 483 | 981 |
GILEAD SCIENCES, INC. is 16.4x more valuable than Krystal Biotech, Inc. by market capitalization ($150.83 B vs $9.21 B).
In their latest fiscal years, Krystal Biotech, Inc. reported $389.13M in revenue while GILEAD SCIENCES, INC. reported $29.44B.
Full pages: Krystal Biotech, Inc. and GILEAD SCIENCES, INC., or browse the full rankings.